It is widely recognized that the efficacy of canonical cancer therapies could be improved by IDH1 inhibition.[44] In pancreatic cancer cells, gemcitabine treatment induces HuR‐dependent IDH1 expression, and the HuR‐IDH1 regulatory axis in turn results in pancreatic cancer cell chemoresistance. This evidence concerns the gene ELAVL1 and pancreatic neoplasm.